ELTP ELITE PHARMACEUTICALS INC /NV/
Pharmaceutical Preparations · OTC · SEC CIK 1053369 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.8%
TTM net income YoY333.0%
TTM EPS YoY50.0%
Revenue 3-yr CAGR52.2%
Net income 3-yr CAGR50.1%
Margins
Gross margin43.7%
Operating margin25.3%
Net margin41.6%
FCF margin6.0%
EBITDA margin26.1%
Returns
ROE65.6%
ROA46.1%
ROIC (approx.)52.7%
Asset turnover1.11x
Leverage & solvency
Liabilities / assets15.3%
Debt / equity0.00x
Current ratio6.65x
Interest coverage338.18x
Cash quality & payout
Operating cash flow / net income0.18x
Accruals ratio37.8%
Payout ratio—
Capex / revenue1.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $40.08M | $32.36M | $40.75M | $31.59M | $36.32M | $40.21M | $32.00M | $14.36M |
| Cost of revenue | $24.09M | $18.85M | $19.98M | $18.64M | $22.25M | $12.99M | $14.70M | $8.24M |
| Gross profit | $15.99M | $13.51M | $20.77M | $12.95M | $14.07M | $27.23M | $17.30M | $6.12M |
| R&D expense | $1.88M | $2.03M | $1.64M | $1.04M | $1.39M | $1.67M | $2.04M | $1.79M |
| SG&A expense | $3.78M | $3.55M | $7.70M | $2.47M | $4.03M | $3.40M | $2.03M | $2.72M |
| Operating income | $9.93M | $7.53M | $10.19M | $9.01M | $8.21M | $21.70M | $11.15M | $1.10M |
| Interest expense | $26,893 | $27,170 | $26,855 | $27,471 | $28,237 | $28,797 | $29,130 | $31,089 |
| Pretax income | $19.74M | $7.72M | $20.85M | $20.83M | $15.69M | -$564,214 | $19.27M | -$10.65M |
| Income tax | $2.43M | $1.81M | $2.39M | $2.24M | $1.99M | $5.32M | $2.27M | $239,175 |
| Net income | $17.32M | $5.91M | $18.46M | $18.59M | $13.70M | -$5.88M | $17.00M | -$10.89M |
| EBITDA | $10.31M | $7.78M | $10.44M | $9.28M | $8.61M | $21.98M | $11.44M | $1.41M |
| EPS (basic) | 0.02 | 0.01 | — | 0.02 | 0.01 | -0.01 | — | -0.01 |
| EPS (diluted) | 0.01 | 0.01 | — | 0.01 | 0.01 | -0.01 | — | -0.01 |
| Weighted avg. shares (diluted) | 1.12B | 1.13B | — | 1.14B | 1.14B | 1.07B | — | 1.07B |
| Balance sheet | ||||||||
| Cash & equivalents | $35.34M | $39.42M | $29.80M | $21.56M | $27.08M | $22.20M | $11.77M | $8.74M |
| Receivables | $63.22M | $50.44M | $59.72M | $48.53M | $40.87M | $36.22M | $29.21M | $18.45M |
| Inventory | $22.52M | $24.20M | $21.26M | $25.10M | $18.16M | $19.36M | $16.24M | $20.16M |
| Current assets | $120.74M | $114.49M | $112.11M | $96.79M | $85.79M | $77.86M | $57.74M | $48.05M |
| PP&E, net | $11.20M | $10.74M | $10.18M | $10.04M | $10.10M | $10.27M | $10.33M | $9.86M |
| Intangibles | $4.79M | $4.79M | $4.79M | $5.64M | $5.64M | $5.64M | $5.64M | $7.24M |
| Total assets | $144.29M | $139.67M | $138.29M | $126.41M | $117.25M | $111.34M | $96.39M | $90.76M |
| Current liabilities | $18.15M | $30.44M | $17.39M | $13.19M | $10.67M | $10.76M | $11.84M | $14.69M |
| Total liabilities | $22.12M | $34.84M | $39.41M | $46.10M | $55.66M | $63.66M | $42.87M | $54.31M |
| Shareholders' equity | $122.17M | $104.83M | $98.88M | $80.31M | $61.58M | $47.68M | $53.52M | $36.45M |
| Shares outstanding | 1.08B | 1.08B | 1.08B | 1.07B | 1.07B | 1.07B | 1.07B | 1.07B |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.07M | $10.07M | $9.15M | -$5.28M | $5.10M | $14.78M | $3.92M | -$1.06M |
| Capital expenditure | $732,184 | $808,964 | $398,016 | $206,072 | $103,334 | $218,204 | $754,110 | $0 |
| Free cash flow | -$3.81M | $9.26M | $8.75M | -$5.48M | $5.00M | $14.56M | $3.16M | -$1.06M |
| Investing cash flow | -$732,184 | -$808,964 | -$398,016 | -$206,072 | -$103,334 | -$218,204 | -$754,110 | $0 |
| Financing cash flow | -$266,362 | -$114,594 | -$41,522 | -$33,635 | -$116,468 | -$4.13M | -$137,044 | -$193,104 |
| Depreciation & amortization | $382,456 | $252,975 | $252,077 | $268,662 | $394,864 | $275,413 | $290,392 | $313,060 |
| Stock-based compensation | $20,307 | $28,476 | $29,164 | $45,096 | $49,918 | $52,329 | $52,329 | $70,578 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.